Sat.Sep 28, 2024 - Fri.Oct 04, 2024

article thumbnail

Big Pharma's layoff wave in New Jersey rolls on with hundreds of J&J cuts, 57 at Bayer

Fierce Pharma

Johnson & Johnson is laying off 231 employees in New Jersey and Bayer is cutting 57 positions in the state, according to separate Worker Adjustment and Retraining Notification (WARN)

Pharma 338
article thumbnail

First Do No Harm: Support Legislative Efforts to Combat the Adverse Drug Event Epidemic 

MedCity News

The Hippocratic oath can’t stop with direct patient care; the healthcare industry and its key stakeholders must address persistent public health problems systematically. We have the tools to reduce medication harm by half or more; it is long past time to make this a public health priority. The post First Do No Harm: Support Legislative Efforts to Combat the Adverse Drug Event Epidemic appeared first on MedCity News.

Medical 123
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Amgen to face investor lawsuit over $10.7bn tax liability disclosure

pharmaphorum

A federal judge in New York has ruled that Amgen must answer to claims of misleading investors about billions owed to US tax authorities, allowing a securities-fraud class action to proceed against the pharmaceutical giant.

article thumbnail

AAPS PharmSci 360 2024: Drug Delivery in Early Development

PharmaTech

Pharmaceutical Technology sat down with Erica Schlesinger, vice president of technical development at Serán Bioscience, to talk about her upcoming presentation at AAPS PharmSci 360 2024, “High Dose Subcutaneous Delivery of Protein Therapeutics.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

US' top IV fluid maker Baxter voices uncertainty about recovery timeline at NC facility hit by Helene

Fierce Pharma

After announcing the closure of its biggest manufacturing site Sunday due to flooding caused by Hurricane Helene, Baxter International—the U.S.’ top supplier of hospital IV fluids—is laying out det | While progress is already being made after Hurricane Helene, which resulted in water “permeating” Baxter’s large IV fluid production plant in North Carolina, the company cautioned that it does not yet have a timeline for when operations will be back online.

article thumbnail

The FTC Is Suing PBMs Over Insulin Prices. Will It Be Successful?

MedCity News

The Federal Trade Commission has sued CVS Caremark, Express Scripts and Optum Rx, alleging that they engage in “anticompetitive and unfair rebating practices” as it relates to insulin. One legal expert believes the FTC might win this legal battle. The post The FTC Is Suing PBMs Over Insulin Prices. Will It Be Successful? appeared first on MedCity News.

Patients 133

More Trending

article thumbnail

Neffy nasal spray: a game changer for asthma patients and epinephrine delivery?

Pharmaceutical Technology

The first needle-free epinephrine nasal spray, Neffy by ARS Pharmaceuticals, represents a significant breakthrough in emergency treatment for type I allergic reactions.

Patients 105
article thumbnail

Gilead strikes licensing deals with 6 generics makers to boost access to long-acting HIV PrEP med

Fierce Pharma

Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV candidate lenacapavir. | The company will allow six generic manufacturers to make and sell its long-acting PrEP drug, lenacapivir, in 120 resource-limited countries.

article thumbnail

How A Physician Group Is Using AI to Save Clinicians 3+ Hours Per Day on Documentation

MedCity News

Alpine Physician Partners — which operates primary care organizations in several states — is implementing Ambience Healthcare’s documentation and coding tool after a successful pilot. Before adopting Ambience’s tool, Alpine clinicians spent 4.7 hours on charting per day, but now that time has dropped down to 1.2 hours per day. The post How A Physician Group Is Using AI to Save Clinicians 3+ Hours Per Day on Documentation appeared first on MedCity News.

article thumbnail

Gilead strikes deal to expand HIV drug access in 120 countries

pharmaphorum

Gilead has partnered with six generic manufacturers to expand access to HIV Drug lenacapavir in high-incidence, resource-limited countries following promising clinical trial results.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Enhancing intestinal drug delivery with Quality by Design

European Pharmaceutical Review

A study has reported an approach for optimising metronidazole colonic delivery systems, to increase their potential efficacy when treating diverticulitis. Researchers developed intestinal colon-coated sustained-release matrix metronidazole tablets, using a Quality by Design (QbD) approach. Arévalo-Pérez et al. noted that metronidazole is a synthetic nitroimidazole and has activity against anaerobic bacteria.

article thumbnail

Eli Lilly's shortage of diabetes and obesity drugs is over, halting competition with knock-offs

Fierce Pharma

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, | Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.

article thumbnail

SCAN, Astrana Launch MA Plan Tailored to Asian Older Adults

MedCity News

SCAN Health Plan and Astrana Health recently launched SCAN Allied, a Medicare Advantage plan designed for the Asian older adult population. It includes access to a network of culturally competent providers, specialists and pharmacies from Astrana Health. The post SCAN, Astrana Launch MA Plan Tailored to Asian Older Adults appeared first on MedCity News.

article thumbnail

Exscientia outline robot and AI use in drug discovery workflow

Pharmaceutical Technology

Exscientia detailed how its robotics lab in Oxfordshire, UK is increasing productivity and efficiency in developing new molecules at ELRIG 2024.

110
110
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

After scoring a first for an off-the-shelf CAR-T, can Atara maintain momentum?

PharmaVoice

The company’s allogeneic therapy was OK’d in the EU and could become the first of its kind approved by the FDA in January — while eyeing the next frontier.

FDA 98
article thumbnail

Aspen Neuroscience, underway with Parkinson's cell therapy trial, bolsters manufacturing with new San Diego facility

Fierce Pharma

Aspen Neuroscience, underway with Parkinson's cell therapy trial, bolsters manufacturing with new San Diego facility fkansteiner Wed, 10/02/2024 - 07:31

article thumbnail

Funding In Youth Mental Health Is Growing. Where are the Opportunities?

MedCity News

More investors are becoming interested in digital health startups specifically targeting youth behavioral health. However, there are still more opportunities to reach youth on Medicaid. The post Funding In Youth Mental Health Is Growing. Where are the Opportunities? appeared first on MedCity News.

125
125
article thumbnail

Importance of Pharmacovigilance practices currently in India and globally with the rising drug development processes across the world : An Update

Pharmatutor

Importance of Pharmacovigilance practices currently in India and globally with the rising drug development processes across the world : An Update admin Sat, 09/28/2024 - 14:28 About Author Devansh Mehta, Founder Director, MarketMavericks Digital OPC PVT. LTD. And TRM Writer’s LLP, Meerut, Uttar Pradesh, India. Pin code: 250100.

96
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped?

PharmaVoice

Cassava Sciences’ beleaguered investigational Alzheimer’s therapy is in two phase 3 studies.

125
125
article thumbnail

J&J's Erleada prevails over Astellas, Pfizer’s Xtandi in real-world prostate cancer study

Fierce Pharma

While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi has held a larger slice of the market than Johnson & Johnson’s riva | A real-world, head-to-head study of two androgen receptor pathway inhibiting (ARPI) prostate cancer drugs indicates that Johnson & Johnson’s Erleada provides an edge in overall survival versus Astellas and Pfizer’s Xtandi.

Marketing 300
article thumbnail

Most Healthcare Organizations Have Paid $500K or More in Ransom Post-Cyberattack, Report Says

MedCity News

More than three-quarters of healthcare organizations reported paying more than $500,000 in ransom as a result of cyberattacks, according to a new report. The post Most Healthcare Organizations Have Paid $500K or More in Ransom Post-Cyberattack, Report Says appeared first on MedCity News.

article thumbnail

CCC to Host “Let Licensing Bloom: The Root of Responsible AI” Panel at Frankfurt Book Fair

Copyright Clearance Center

October 1, 2024 – Danvers, Mass. – CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, will host “Let Licensing Bloom: The Root of Responsible AI” on 17 October, 3:00 – 4:00 pm CET at the 2024 Frankfurt Book Fair in Frankfurt Studio Hall 4.0, Room Europa. Panelists include Arend Kuester , CSIRO Publishing; Josh Jarrett , Wiley; Lui Simpson , Association of American Publishers (AAP); and Sarah Tegen , American Chemical Society (ACS).

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Social media algorithms are driving the GLP-1 drugs boom

Pharmaceutical Technology

GLP-1 RAs are being recommended on social media, raising questions about who can see the content and what the effects might be.

Media 105
article thumbnail

CDMOs eye industrywide growth in 2025 as many spurn BIOSECURE Act, CPHI research shows

Fierce Pharma

After experiencing a series of ups and downs in recent years, the biopharma contracting business is gearing up for a rebound in 2025. | Ahead of the CPHI conference in Milan, the events group has teased new research signaling an expected rebound for the CDMO industry—and a rejection of the BIOSECURE Act.

Biopharma 301
article thumbnail

Who Wins When Nurses Are Reimbursed for Care Delivery?

MedCity News

Investing in nurses — by reimbursing them based on the value of their work — can improve job satisfaction thus reducing the churn rate and attracting more to the profession. The post Who Wins When Nurses Are Reimbursed for Care Delivery? appeared first on MedCity News.

Patients 113
article thumbnail

Mounjaro and Zepbound shortages over, declares FDA

pharmaphorum

FDA declares an end to tirzepatide shortage, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro.

FDA 96
article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

LoQus23 secures $43m to advance Huntington’s Disease therapy

Pharmaceutical Technology

The funds will support the development of LoQus23’s lead candidate, its MutSβ inhibitor, as it enters clinical development.

Leads 105
article thumbnail

J&J, Legend solidify Carvykti's lead in earlier multiple myeloma with strong survival showing

Fierce Pharma

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson & Johnson and Legend Biotech’ Carvykti has once again mounted a maj | After putting on a strong performance in preventing disease progression, Johnson & Johnson and Legend Biotech’s Carvykti has once again demonstrated a major benefit—this time in prolonging patients’ lives.

Leads 297
article thumbnail

MedCity Moves Podcast: Recent Hires, Layoffs & an Interview with Dr. Jayne Morgan, VP of Medical Affairs at Hello Heart

MedCity News

In this month’s episode, Senior Reporter Katie Adams explored some of the executive moves, exits and layoffs that recently occurred in the healthcare sector. She also interviewed Dr. Jayne Morgan, who recently became vice president of medical affairs at Hello Heart. The post MedCity Moves Podcast: Recent Hires, Layoffs & an Interview with Dr. Jayne Morgan, VP of Medical Affairs at Hello Heart appeared first on MedCity News.

Medical 118
article thumbnail

AI pathology accelerates with Proscia Concentriq launch

pharmaphorum

Proscia announces launch of Concentriq Embeddings and Proscia AI Toolkit, hoping to accelerate precision medicine R&D.

Medicine 105
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time